Protagonist Therapeutics (PTGX) to Announce Earnings on Wednesday

Protagonist Therapeutics (NASDAQ:PTGX) is projected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $2.23 per share and revenue of $199.8120 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. On average, analysts expect Protagonist Therapeutics to post $4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Protagonist Therapeutics Stock Performance

PTGX opened at $132.28 on Tuesday. The company has a fifty day moving average of $121.04 and a two-hundred day moving average of $103.75. The stock has a market capitalization of $8.51 billion, a price-to-earnings ratio of -73.08 and a beta of 1.78. Protagonist Therapeutics has a fifty-two week low of $50.49 and a fifty-two week high of $143.29.

Analysts Set New Price Targets

PTGX has been the subject of several recent analyst reports. Barclays boosted their price target on shares of Protagonist Therapeutics from $119.00 to $151.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Wolfe Research initiated coverage on shares of Protagonist Therapeutics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 target price on the stock. Wedbush boosted their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Citizens Jmp upped their price target on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Protagonist Therapeutics in a research note on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $123.00.

Insider Buying and Selling

In other news, Director Bryan Giraudo sold 6,000 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $100.00, for a total value of $600,000.00. Following the completion of the sale, the director owned 31,825 shares of the company’s stock, valued at $3,182,500. This represents a 15.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director directly owned 7,825 shares in the company, valued at approximately $922,880.50. The trade was a 53.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 161,130 shares of company stock worth $16,355,220. Insiders own 5.19% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Greenline Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics in the 4th quarter valued at $27,000. Osaic Holdings Inc. raised its holdings in Protagonist Therapeutics by 79.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after buying an additional 525 shares during the period. Quadrant Capital Group LLC purchased a new stake in Protagonist Therapeutics in the 3rd quarter valued at about $90,000. Truvestments Capital LLC lifted its position in Protagonist Therapeutics by 60.8% in the fourth quarter. Truvestments Capital LLC now owns 1,161 shares of the company’s stock valued at $101,000 after buying an additional 439 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Protagonist Therapeutics by 23.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,727 shares of the company’s stock valued at $151,000 after buying an additional 324 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.